广州费米子科技

Fermion Technology is a clinical-stage biotechnology company that utilizes artificial intelligence to revolutionize the discovery and development of small molecule drugs. Based in Guangzhou, China, the company focuses on therapeutic areas with high unmet needs, including chronic pain, central nervous system disorders, and autoimmune diseases. Their proprietary AI platform, Drug Studio, integrates deep learning and computational chemistry to significantly reduce the time and cost of drug development. Fermion's lead candidates, such as FZ002 and FZ008, target specific sodium channels to provide non-opioid solutions for pain management. The company has successfully raised multiple rounds of funding from top-tier investors like Sequoia China and IDG Capital. Fermion continues to expand its pipeline through both internal development and strategic partnerships with pharmaceutical leaders.